Blair William & Co. IL Has $312,000 Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Blair William & Co. IL grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 25.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,531 shares of the specialty pharmaceutical company’s stock after acquiring an additional 509 shares during the quarter. Blair William & Co. IL’s holdings in Jazz Pharmaceuticals were worth $312,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Townsquare Capital LLC bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $220,000. Captrust Financial Advisors raised its position in Jazz Pharmaceuticals by 9.5% in the third quarter. Captrust Financial Advisors now owns 4,965 shares of the specialty pharmaceutical company’s stock valued at $553,000 after purchasing an additional 430 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 37.2% during the third quarter. HighTower Advisors LLC now owns 7,594 shares of the specialty pharmaceutical company’s stock valued at $851,000 after purchasing an additional 2,060 shares in the last quarter. Quarry LP bought a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $178,000. Finally, Quantinno Capital Management LP increased its stake in shares of Jazz Pharmaceuticals by 268.5% in the third quarter. Quantinno Capital Management LP now owns 58,913 shares of the specialty pharmaceutical company’s stock valued at $6,563,000 after buying an additional 42,924 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 in the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JAZZ. Piper Sandler reiterated an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Barclays restated an “overweight” rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. JPMorgan Chase & Co. lifted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $187.71.

Jazz Pharmaceuticals Stock Down 8.9 %

Shares of NASDAQ JAZZ opened at $110.04 on Friday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market cap of $6.68 billion, a PE ratio of 15.50, a P/E/G ratio of 1.04 and a beta of 0.42. The company’s fifty day simple moving average is $132.27 and its 200 day simple moving average is $122.99.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.